The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
Ovarian cancer (OvCA) accounts for one of the leading causes of death from gynecologic malignancy. Despite progress in therapy improvements in OvCA, most patients develop a recurrence after first-line treatments, dependent on the tumor and non-tumor complexity/heterogeneity of the neoplasm and its s...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/9/3125 |
id |
doaj-04b571268dd548b9abfb101445b55662 |
---|---|
record_format |
Article |
spelling |
doaj-04b571268dd548b9abfb101445b556622020-11-25T02:10:32ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-04-01213125312510.3390/ijms21093125The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic EffectorsDenisa Baci0Annalisa Bosi1Matteo Gallazzi2Manuela Rizzi3Douglas M. Noonan4Alessandro Poggi5Antonino Bruno6Lorenzo Mortara7Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, ItalyLaboratory of Pharmacology, Department of Medicine and Surgery, University of Insubria, 21100 Varese, ItalyImmunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, ItalyImmunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, ItalyImmunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, ItalyUOSD Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, ItalyIRCCS MultiMedica, 20138 Milan, ItalyImmunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, ItalyOvarian cancer (OvCA) accounts for one of the leading causes of death from gynecologic malignancy. Despite progress in therapy improvements in OvCA, most patients develop a recurrence after first-line treatments, dependent on the tumor and non-tumor complexity/heterogeneity of the neoplasm and its surrounding tumor microenvironment (TME). The TME has gained greater attention in the design of specific therapies within the new era of immunotherapy. It is now clear that the immune contexture in OvCA, here referred as tumor immune microenvironment (TIME), acts as a crucial orchestrator of OvCA progression, thus representing a necessary target for combined therapies. Currently, several advancements of antitumor immune responses in OvCA are based on the characterization of tumor-infiltrating lymphocytes, which have been shown to correlate with a significantly improved clinical outcome. Here, we reviewed the literature on selected TIME components of OvCA, such as macrophages, neutrophils, γδ T lymphocytes, and natural killer (NK) cells; these cells can have a role in either supporting or limiting OvCA, depending on the TIME stimuli. We also reviewed and discussed the major (immune)-therapeutic approaches currently employed to target and/or potentiate macrophages, neutrophils, γδ T lymphocytes, and NK cells in the OvCA context.https://www.mdpi.com/1422-0067/21/9/3125ovarian cancerinnate immune cellstumor microenvironmentmacrophagesinnate immune cell targeted therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Denisa Baci Annalisa Bosi Matteo Gallazzi Manuela Rizzi Douglas M. Noonan Alessandro Poggi Antonino Bruno Lorenzo Mortara |
spellingShingle |
Denisa Baci Annalisa Bosi Matteo Gallazzi Manuela Rizzi Douglas M. Noonan Alessandro Poggi Antonino Bruno Lorenzo Mortara The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors International Journal of Molecular Sciences ovarian cancer innate immune cells tumor microenvironment macrophages innate immune cell targeted therapy |
author_facet |
Denisa Baci Annalisa Bosi Matteo Gallazzi Manuela Rizzi Douglas M. Noonan Alessandro Poggi Antonino Bruno Lorenzo Mortara |
author_sort |
Denisa Baci |
title |
The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors |
title_short |
The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors |
title_full |
The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors |
title_fullStr |
The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors |
title_full_unstemmed |
The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors |
title_sort |
ovarian cancer tumor immune microenvironment (time) as target for therapy: a focus on innate immunity cells as therapeutic effectors |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2020-04-01 |
description |
Ovarian cancer (OvCA) accounts for one of the leading causes of death from gynecologic malignancy. Despite progress in therapy improvements in OvCA, most patients develop a recurrence after first-line treatments, dependent on the tumor and non-tumor complexity/heterogeneity of the neoplasm and its surrounding tumor microenvironment (TME). The TME has gained greater attention in the design of specific therapies within the new era of immunotherapy. It is now clear that the immune contexture in OvCA, here referred as tumor immune microenvironment (TIME), acts as a crucial orchestrator of OvCA progression, thus representing a necessary target for combined therapies. Currently, several advancements of antitumor immune responses in OvCA are based on the characterization of tumor-infiltrating lymphocytes, which have been shown to correlate with a significantly improved clinical outcome. Here, we reviewed the literature on selected TIME components of OvCA, such as macrophages, neutrophils, γδ T lymphocytes, and natural killer (NK) cells; these cells can have a role in either supporting or limiting OvCA, depending on the TIME stimuli. We also reviewed and discussed the major (immune)-therapeutic approaches currently employed to target and/or potentiate macrophages, neutrophils, γδ T lymphocytes, and NK cells in the OvCA context. |
topic |
ovarian cancer innate immune cells tumor microenvironment macrophages innate immune cell targeted therapy |
url |
https://www.mdpi.com/1422-0067/21/9/3125 |
work_keys_str_mv |
AT denisabaci theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT annalisabosi theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT matteogallazzi theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT manuelarizzi theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT douglasmnoonan theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT alessandropoggi theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT antoninobruno theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT lorenzomortara theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT denisabaci ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT annalisabosi ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT matteogallazzi ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT manuelarizzi ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT douglasmnoonan ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT alessandropoggi ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT antoninobruno ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT lorenzomortara ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors |
_version_ |
1724919141579620352 |